Waiv
AI precision testing for oncology.
Paris, France · Founded 2026 · $33.0M raised
- Headquarters
- Paris
- Employees
- 11–50
- Founded
- 2026
- Business Model
- B2B
- Website
- we-are-waiv.com
- Total Funding
- $33.0M
- Last Round
- $33.0M Venture RoundMar 2026
- Rounds
- 1
About
Waiv (formerly Owkin Dx) is a Paris-based AI precision testing company spun out of biotech firm Owkin in 2026 with $33M in Series A funding. Built on 7+ years of clinical AI development, Waiv offers AI pathology models for oncology including cancer diagnostics, leveraging one of Europe's largest multi-institutional medical data networks.
Summary
Waiv is a Healthcare company based in Paris, France, founded in 2026. It has raised $33.0M in total across 1 round, most recently a $33.0M Venture Round round in Mar 2026.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Similar Companies
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Hyland provides content services and intelligent automation solutions for enterprises.
Healthcare cost management company providing data analytics and network-based payment solutions t...
American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...